Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 01:08 ET | Source: Genmab A/S

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds...
September 25, 2025 19:14 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants...
September 23, 2025 09:18 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
September 09, 2025 14:57 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
September 09, 2025 14:54 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The...
September 03, 2025 08:30 ET | Source: Genmab A/S

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
August 26, 2025 09:31 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; August 26, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will...
August 26, 2025 08:00 ET | Source: Genmab A/S

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have...
August 12, 2025 14:36 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The...
August 07, 2025 11:08 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for...